<DOC>
	<DOC>NCT02706730</DOC>
	<brief_summary>This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201102 (Phase 2b study of OTO-104) or 104-201506 (Phase 3 study of OTO-104) in order to be eligible for this open-label extension study.</brief_summary>
	<brief_title>A 6-Month Extension Study of OTO-104 in Meniere's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject has completed the OTO104 Phase 2b (104201102) or Phase 3 (104201506) clinical study. Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAOHNS criteria Exclusion Criteria includes, but is not limited to: Subject is pregnant or lactating. Subject has a history of immunodeficiency disease. Subject has experienced an adverse reaction to intratympanic injection of steroids.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>